NLS Pharmaceutics AG (NLSP) Stock Analysis

NLS Pharmaceutics AG (NLSP) is a publicly traded company in the HEALTHCARE sector. It trades at $3.48. This page summarizes the public market data, fundamentals, and frequently asked questions for NLSP, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About NLS Pharmaceutics AG

NLS Pharmaceutics AG is a biopharmaceutical company headquartered in Stans, Switzerland, dedicated to the innovative discovery and development of drug therapies for rare and complex central nervous system (CNS) disorders. The company’s robust pipeline of novel therapeutics aims to meet significant unmet medical needs, utilizing proprietary technologies and extensive research initiatives. With a strong commitment to enhancing patient outcomes, NLS Pharmaceutics is poised to establish itself as...

GNG Research Analysis

GNG Research scores NLS Pharmaceutics AG (NLSP) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NLSP.

Frequently Asked Questions

Does NLSP pay dividends?

NLS Pharmaceutics AG (NLSP) does not currently pay a regular dividend.